Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000525837 | SCV000638010 | uncertain significance | Familial hypocalciuric hypercalcemia; Autosomal dominant hypocalcemia 1 | 2024-06-28 | criteria provided, single submitter | clinical testing | This sequence change replaces histidine, which is basic and polar, with glutamine, which is neutral and polar, at codon 429 of the CASR protein (p.His429Gln). This variant is present in population databases (rs746515147, gnomAD 0.02%). This missense change has been observed in individual(s) with hypoparathyroidism and/or primary hyperparathyroidism (PMID: 31433868, 35586626). ClinVar contains an entry for this variant (Variation ID: 463895). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004023929 | SCV001171005 | uncertain significance | Nephrolithiasis/nephrocalcinosis | 2023-04-25 | criteria provided, single submitter | clinical testing | The p.H429Q variant (also known as c.1287C>A), located in coding exon 3 of the CASR gene, results from a C to A substitution at nucleotide position 1287. The histidine at codon 429 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002476143 | SCV002778903 | uncertain significance | Familial hypocalciuric hypercalcemia 1; Neonatal severe primary hyperparathyroidism; Epilepsy, idiopathic generalized, susceptibility to, 8; Autosomal dominant hypocalcemia 1 | 2023-12-29 | criteria provided, single submitter | clinical testing |